Guide for patients & caregivers

Atypical Lobular Hyperplasia on Breast Biopsy: What Does It Mean?

Atypical lobular hyperplasia (ALH) on a breast biopsy explained: why it is not cancer, how it marks a higher risk, follow-up imaging and questions to ask.

By SameCase EditorialUpdated 6 min read

Prepared with AI assistance and checked against the cited sources. No independent clinician review has been completed. How we prepare articles

What is atypical lobular hyperplasia on a breast biopsy?

Atypical lobular hyperplasia (ALH) means the pathologist saw an increased number of unusual-looking cells inside some of the breast lobules, the small glands that make milk. ALH is benign, meaning it is not cancer. It matters mainly because it is linked with a somewhat higher chance of breast cancer in the future, in either breast, so it usually leads to a follow-up plan rather than cancer treatment.

This guide explains the report wording for adults who already have an ALH result. It cannot tell anyone what their own result means for them; the breast team reads the biopsy together with the imaging and personal history.

When to get checked sooner

A biopsy result does not replace attention to new symptoms. The NHS advises seeing a GP or doctor about a new lump or swelling in the breast, chest or armpit, or any change that is not normal for you. Do not wait for a planned follow-up mammogram if something changes.

  • A new lump or swelling in the breast, chest or armpit.
  • Dimpling of the skin, or a change in skin colour or texture.
  • A change in the size or shape of a breast.
  • Nipple discharge when not pregnant or breastfeeding, especially if it contains blood.
  • A nipple that turns inwards or develops a rash.
  • After a biopsy or excision: bleeding that firm pressure does not stop, bruising that keeps getting worse, or a breast that becomes hot, red and swollen. Contact the breast team, GP or local urgent services as advised on your aftercare sheet.

Is ALH the same as lobular neoplasia or LCIS?

Reports may use several related terms. Breast Cancer Now and Cancer Research UK describe lobular neoplasia as the umbrella name for ALH and lobular carcinoma in situ (LCIS). ALH looks very similar to classic LCIS under the microscope but involves fewer abnormal cells. Pathologists can find the two hard to separate, so some reports simply say lobular neoplasia.

Despite its name, classic LCIS is also not cancer. In situ means the changes stay inside the lobules and do not affect the surrounding breast tissue. Rarer types called pleomorphic or florid LCIS have larger, more abnormal cells and are often managed more like ductal carcinoma in situ (DCIS). If your report uses any of these words, ask which type was seen.

ALH is also different from invasive lobular breast cancer, which is a type of breast cancer. The similar names cause understandable confusion, so it is reasonable to ask the team to confirm exactly what was found.

How is ALH usually found?

ALH does not usually cause a lump or other symptoms, and it often does not show up on a mammogram. It is usually found by chance when tissue is taken to investigate something else, such as small calcium spots (calcifications) on a mammogram or another breast change. The finding that led to the biopsy and the ALH may therefore be two different things.

That is why the team compares the pathology result with the images. They want to know whether the biopsy explains what was seen on the scan. When the two do not match, extra sampling is more likely.

Will more tissue need to be removed?

Not always. When lobular neoplasia is found on a core needle biopsy, Breast Cancer Now says the team may recommend removing more tissue from the same area to check for any cancer cells. This may be another core biopsy, a vacuum-assisted excision (a needle connected to a vacuum device, done under local anaesthetic) or a small operation called an excision biopsy.

An international consensus on these borderline (often reported as B3) lesions describes common reasons for taking more tissue: a lesion that is visible on imaging, another finding that needs removal, or a mismatch between the images and the pathology. Practice differs between countries and hospitals. Classic ALH itself does not usually need treatment, according to Breast Cancer Now and Cancer Research UK.

What does ALH mean for breast cancer risk?

Most people with ALH or classic LCIS never develop breast cancer, according to Breast Cancer Now. The risk is described as slightly higher than in the general population and applies to either breast. Cleveland Clinic states that people with either type of atypical hyperplasia may be up to four times more likely to get breast cancer than people without it.

Those are group figures, not a forecast for any one person. Individual risk also depends on age, family history, breast density and other factors, which the team can weigh together. Some people are referred for a family history or risk assessment.

What follow-up and screening are usual after ALH?

Follow-up is decided case by case. Cancer Research UK says people with classic LCIS may have a mammogram every year for five years, and Breast Cancer Now says the team may recommend a different plan for ALH. If other risk factors exist, such as a significant family history or dense breasts, MRI may be suggested.

Depending on the situation, the team may discuss hormone (endocrine) therapy to lower future risk. This is a personal decision that weighs possible benefits against side effects. Breast Cancer Now also notes that HRT and oral contraceptives (the pill) are not usually recommended after lobular neoplasia. If you already take either, do not stop or change a prescribed medicine without talking to the prescriber; raise it at your next appointment.

Questions to ask the breast team

Writing questions down before the appointment can help. These may be useful:

  • Was this ALH, classic LCIS or another type of lobular neoplasia?
  • Does the biopsy result match what was seen on my mammogram or ultrasound?
  • Do I need more tissue removed, and by which method?
  • What follow-up imaging do you recommend, how often and for how long?
  • Do my family history or breast density change that plan?
  • Should I have a risk assessment or discuss risk-reducing treatment?
  • What changes should make me contact you before my next scan?

How can SameCase help you prepare?

On SameCase, patients and verified doctors share de-identified cases. Reading how others with a similar biopsy report described their follow-up can help you notice questions you had not thought of, such as how imaging and pathology were compared. Other people's paths are examples, not a guide to your own; your breast team makes the decisions about your care.

Sources and further reading

For patients & caregivers

Share your case and learn from others

Learn from doctors and other people's cases to find a way forward with your health problem. New cases are public immediately. Don't add names or identifying details.

Keep learning